Analysts Issue Forecasts for Zoetis’ Q1 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Investment analysts at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Zoetis in a report issued on Monday, February 10th. Leerink Partnrs analyst D. Clark now expects that the company will earn $1.43 per share for the quarter, down from their previous forecast of $1.49. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. Leerink Partnrs also issued estimates for Zoetis’ Q2 2025 earnings at $1.62 EPS, Q3 2025 earnings at $1.64 EPS, Q4 2025 earnings at $1.49 EPS, FY2025 earnings at $6.19 EPS, FY2026 earnings at $6.96 EPS, FY2027 earnings at $7.62 EPS and FY2028 earnings at $8.31 EPS.

Several other equities research analysts have also commented on ZTS. Morgan Stanley reduced their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Piper Sandler lowered their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research report on Monday. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis has an average rating of “Buy” and an average price target of $214.00.

Zoetis Stock Up 0.2 %

ZTS stock opened at $171.71 on Tuesday. The company has a market cap of $77.47 billion, a price-to-earnings ratio of 32.28, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The business’s 50-day moving average is $169.26 and its two-hundred day moving average is $179.21. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Institutional Trading of Zoetis

Several hedge funds have recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC grew its holdings in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. grew its holdings in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in Zoetis during the third quarter valued at $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the 3rd quarter valued at about $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in Zoetis during the third quarter valued at approximately $33,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.16%. Zoetis’s payout ratio is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.